Atreca to Present at Upcoming Virtual Investor Conferences
Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), will participate in two upcoming virtual investor conferences: the HC Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, and the Baird Global Healthcare Conference on September 14-15, 2021. The HC Wainwright presentation will be available on-demand starting September 13 at 7:00 a.m. EDT. Atreca focuses on developing novel therapeutics through its unique discovery platform, with its lead candidate ATRC-101 currently undergoing clinical trials.
- None.
- None.
SAN CARLOS, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming virtual investor conferences:
HC Wainwright 23rd Annual Global Investment Conference
September 13-15, 2021
Presentation available beginning September 13
Baird Global Healthcare Conference
September 14-15, 2021
Fireside chat time: 3:00 p.m. EDT, Wednesday, September 15
An audio webcast of the HC Wainwright presentation will be available on-demand beginning at 7:00 a.m. Eastern Time on September 13, 2021, and can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. The presentation will be available on the Company's website for 90 days.
About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and typically are identified by use of terms such as "continued," "anticipate," "potential," "expect," "believe," "planned," and similar words, although some forward-looking statements are expressed differently. These statements include those related to our strategy and future plans, including statements regarding the development of ATRC-101 and our preclinical, clinical and regulatory plans and the timing thereof. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our filings with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.
Contacts
Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com
Investors:
Alex Gray, 650-779-9251, ext. 251
agray@atreca.com
Media:
Sheryl Seapy, 213-262-9390
sseapy@w2ogroup.com
Source: Atreca, Inc.
FAQ
When will Atreca present at the HC Wainwright Conference 2021?
What dates is the Baird Global Healthcare Conference taking place in 2021?
How can I access Atreca's presentation from the HC Wainwright Conference?
What is Atreca's lead product candidate?
Where can I find more information about Atreca's clinical trials?
